Why are CJC-1295 and Ipamorelin combined?

They are researched together because their mechanisms are complementary within the same axis: CJC-1295 acts as a GHRH analog and Ipamorelin acts on the ghrelin receptor, two parallel pathways that converge on the somatotroph cell. This is a mechanistic rationale described in the literature, not demonstrated efficacy in controlled trials or a recommendation for use. We give no dosing guidance; in the master's course we analyze these mechanisms with the primary sources.

Are they approved or allowed in sport?

No. Neither CJC-1295 nor Ipamorelin is approved by the FDA, EMA, or MHRA as a drug for human use; they are sold and referenced as RUO products. As growth hormone-axis secretagogues, they are included on the World Anti-Doping Agency (WADA) prohibited list. Regulatory status varies by jurisdiction and can change.

← Guides

CJC-1295 and Ipamorelin: what they are and how they work

CJC-1295 and Ipamorelin are two research peptides frequently mentioned together because they act on the same system — the growth hormone (GH) axis — but through different pathways. This guide explains, at an educational level, what each one is, why their mechanisms are studied as complementary, and what the available evidence actually shows. It is not medical advice or a recommendation for use, and it includes no dosing guidance: research peptides are not approved for human use in most jurisdictions.

What CJC-1295 is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH 1-29), chemically modified to better resist enzymatic degradation. In its DAC (Drug Affinity Complex) form it is engineered to bind circulating albumin after injection, extending its functional half-life from the minutes of native GHRH to several days. It acts on pituitary GHRH receptors to stimulate GH release. Human pharmacology studies note that, despite this prolonged exposure, the physiological pulsatile pattern of GH secretion tends to be preserved rather than becoming continuous.

What Ipamorelin is

Ipamorelin is a synthetic pentapeptide studied as a selective agonist of the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells. Activation of that receptor is associated with stimulating pulsatile release of endogenous GH. Unlike earlier growth hormone-releasing peptides (such as GHRP-6 or GHRP-2), preclinical studies found ipamorelin did not meaningfully raise ACTH, cortisol, or prolactin at GH-stimulating doses, which is why the literature describes it as a more 'selective' secretagogue. In other words, it acts on a different target from CJC-1295 within the same axis.

Why they are researched together

The interest in studying them together stems from their complementary mechanisms on the same axis: CJC-1295 acts as a GHRH analog and Ipamorelin acts on the ghrelin receptor (GHS-R1a). In GH-axis physiology, GHRH and ghrelin-type signaling operate through parallel pathways that converge on the somatotroph cell, so at a theoretical level it is proposed that activating both simultaneously could have a combined effect on pulsatile GH release. It is worth stressing that this describes the mechanistic rationale for why they are studied together; it is not demonstrated efficacy or a recommendation to combine them.

What the evidence says and their legal status

The evidence is limited and early-phase. For CJC-1295 it comes mainly from short-duration pharmacokinetic/pharmacodynamic studies in healthy volunteers; for Ipamorelin it is largely preclinical, with a human trial in a different context (gastrointestinal motility). There is no long-term controlled-trial evidence on body composition, athletic performance, or anti-aging, nor controlled studies of the combination in healthy adults. Both are RUO (research use only) products, not approved by the FDA, EMA, or MHRA for human use, and as GH-axis secretagogues they appear on the World Anti-Doping Agency (WADA) prohibited list in sport.

Frequently asked questions

What are CJC-1295 and Ipamorelin?: They are two research peptides that act on the growth hormone axis. CJC-1295 is a synthetic GHRH analog modified for greater stability; Ipamorelin is a pentapeptide studied as a selective agonist of the ghrelin receptor (GHS-R1a). Both are referenced as RUO (research use only) products and are not approved for human use. This information is educational and not medical advice.
Why are CJC-1295 and Ipamorelin combined?: They are researched together because their mechanisms are complementary within the same axis: CJC-1295 acts as a GHRH analog and Ipamorelin acts on the ghrelin receptor, two parallel pathways that converge on the somatotroph cell. This is a mechanistic rationale described in the literature, not demonstrated efficacy in controlled trials or a recommendation for use. We give no dosing guidance; in the master's course we analyze these mechanisms with the primary sources.
Are they approved or allowed in sport?: No. Neither CJC-1295 nor Ipamorelin is approved by the FDA, EMA, or MHRA as a drug for human use; they are sold and referenced as RUO products. As growth hormone-axis secretagogues, they are included on the World Anti-Doping Agency (WADA) prohibited list. Regulatory status varies by jurisdiction and can change.

This guide is an excerpt of the educational approach of Master of Peptides. The full master's includes the cited encyclopedia, practical tools, exam and certificate.

See the master's →

✓ Last reviewed · 2026-07-22